Upstate Active Clinical Trials
Study Title:
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared with Insulin Degludec in Participants with Type 1 Diabetes Treated with Multiple Daily Injection Therapy.What is the purpose of the study? (in Layman's terms, please describe the study)
The study is being done to see how safe a once-weekly investigational drug is and how it will work to help people with type 1 diabetes who are treated with multiple daily injections of insulin.Upstate Institutional Review Board (IRB) Number:
1904064Study/Protocol ID:
QWINT-5/I8H-MC-BDCYStudy Phase:
3Patient Age Group:
AdultsPrincipal Investigator:
Ruth S Weinstock, MD, PhDWhat is involved if I participate?
- How long is the study?
Participation lasts about 60 weeks. - Is transportation provided or reimbursed?
Yes - Is parking provided or reimbursed?
Yes - What tests and procedures are involved?
Vital signs, physical exam, blood and urine tests, electrocardiogram (ECG), continuous glucose monitoring, questionnaires and electronic study diary completion, diabetes counseling.
Where will the study take place?
Clinical Research Unit at the Institute for Human PerformanceOther Information:
Participants will be paid for completed study visits.ClinicalTrials.Gov ID:
NCT05463744For more information about this trial go to ClinicalTrials.Gov
Who can I contact for more information?
Name: Suzan M Bzdick, RN
Phone: 315-464-9006
Email: bzdicks@upstate.edu